Allopurinol pharmacogenetics: assessment of potential clinical usefulness

作者：Zineh Issam^*; Mummaneni Padmaja; Lyndly Jenna; Amur Shashi; La Grenade Lois A; Chang Stephen H; Rogers Hobart; Pacanowski Michael A

来源：Pharmacogenomics, 2011, 12(12): 1741-1749.

DOI：10.2217/PGS.11.131

• adverse reaction
• allopurinol
• HLA-B*5801
• safety
• SCAR
• Stevens-Johnson syndrome
• US FDA

Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.

• 出版日期2011-12